TY - JOUR
T1 - Editorial
T2 - Mesenchymal Stromal Cell Therapy for Regenerative Medicine
AU - Capilla-González, Vivian
AU - Herranz-Pérez, Vicente
AU - Sarabia-Estrada, Rachel
AU - Kadri, Nadir
AU - Moll, Guido
N1 - Funding Information:
VC-G receives support of the Consejería de Transformación Económica, Industria, Conocimiento y Universidades co-funded by Fondos FEDER (PY20/00481), the Institute of Health Carlos III co-funded by Fondos FEDER (CP19/00046 and PI20/00341), the Fundación Científica de la Asociación Española Contra el Cáncer (IDEAS20051CAPI), and the Asociación Pablo Ugarte (+VIDA project). VH-P receives funding from the Spanish Ministry of Science, Innovation and Universities (PCI2018-093062) and the Valencian Council for Innovation, Universities Science and Digital Society (PROMETEO/2019/075). Contributions from GM were made possible by the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF) through the BSRT (GSC203) and BCRT, respectively, and in part supported by the European Union's Horizon 2020 Research and Innovation Program (Horizon 2020 Framework Program) under the Grant Agreements No. 733006 (PACE) and No. 779293 (HIPGEN).
PY - 2022/5/26
Y1 - 2022/5/26
KW - clinical translation
KW - immunomodulation
KW - mesenchymal stromal/stem cell (MSC)
KW - modes of action (MoA)
KW - regeneration
UR - http://www.scopus.com/inward/record.url?scp=85131130460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131130460&partnerID=8YFLogxK
U2 - 10.3389/fncel.2022.932281
DO - 10.3389/fncel.2022.932281
M3 - Editorial
AN - SCOPUS:85131130460
SN - 1662-5102
VL - 16
JO - Frontiers in Cellular Neuroscience
JF - Frontiers in Cellular Neuroscience
M1 - 932281
ER -